Q4 2025 Earnings Call March 18, 2026 6:00 PM EDTCompany ParticipantsSamuel Cochrane - CEO & Interim CFOConference ...
When the U.S. Food and Drug Administration (FDA) approved Ozempic (semaglutide) in 2017 for adults with type 2 diabetes, it ushered in a new era of blood sugar and weight loss drugs. Since then, the ...
Q4 2025 earnings call recap: record $427.5M revenue, margins hit by impairment, and 2026 ramp plans—read key insights now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results